SeaStar Medical (NASDAQ:ICU) Posts Earnings Results, Misses Expectations By $0.08 EPS

SeaStar Medical (NASDAQ:ICU) announced its quarterly earnings data on Wednesday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08), FiscalAI reports. SeaStar Medical had a negative return on equity of 188.47% and a negative net margin of 984.60%.The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.44 million.

Here are the key takeaways from SeaStar Medical’s conference call:

• SeaStar said QUELIMMUNE net revenue rose nearly 70% year over year to $495,000 in Q1 2026, driven by seven new hospital adoptions, and the company reiterated its full-year revenue target of about $2 million.
• The company reported continued progress in the NEUTRALIZE-AKI adult AKI pivotal trial, with 198 of 339 patients enrolled and additional sites being added to support completion of enrollment around year-end 2026.
• Management is working with the FDA on a modular PMA approach for adult AKI and on a potential rapid approval pathway for its SCD therapy, which they believe could speed review if trial results are positive.
• SeaStar highlighted growing clinical recognition of its technology, citing strong interest at the AKI & CRRT meeting, coverage in ASN Kidney News, and repeat ordering behavior from hospitals once they gain experience with the therapy.
• Financially, operating expenses were essentially flat at about $4.1 million, gross margin remained above 90%, and the company ended the quarter with $9.3 million in cash, while guiding for modest R&D expense increases and steady G&A spending through 2026.

SeaStar Medical Price Performance

NASDAQ ICU traded down $0.24 on Wednesday, hitting $4.60. 72,650 shares of the company were exchanged, compared to its average volume of 87,554. SeaStar Medical has a twelve month low of $2.07 and a twelve month high of $13.40. The company’s 50 day moving average price is $3.56 and its 200-day moving average price is $3.33.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ICU shares. Maxim Group set a $6.00 price objective on shares of SeaStar Medical in a report on Thursday, February 12th. Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell” and a consensus price target of $6.00.

Institutional Trading of SeaStar Medical

Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new position in shares of SeaStar Medical in the third quarter worth $102,000. Jane Street Group LLC bought a new stake in SeaStar Medical during the fourth quarter worth approximately $30,000. Finally, XTX Topco Ltd boosted its holdings in shares of SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after buying an additional 48,674 shares during the period. 1.69% of the stock is owned by hedge funds and other institutional investors.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.